【lunar new year macarons】Helius Medical Technologies, Inc. to Present at Upcoming Investor Conferences in November
NEWTOWN,lunar new year macarons Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:
HSDT
) (TSX:
HSM
) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the following upcoming investor conferences:
The Investor Summit Group’s Virtual Fall Summit, which is being held from November 16th - 18th.
Management will present on Tuesday, November 17th at 1:00 p.m. Eastern Time.
Alliance Global Partners’ Virtual Healthcare Symposium, which is being held on November 19th.
Management will participate in virtual 1x1 meetings on Thursday, November 19th. There will be no formal presentation.
The
Sidoti
& Co. Virtual Fall Microcap Conference, which is being held on November 19th.
Management will present on Thursday, November 19th at 9:15 a.m. Eastern Time.
Live audio webcasts of the presentations will be provided under the ‘Events’ section of the Helius Medical Technologies investor relations website at
https://heliusmedical.com/index.php/investor-relations/events/upcoming-events
. Archives of the webcasts will be available for replay following the conference.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS
TM
). For more information, visit
www.heliusmedical.com
.
About the PoNS™ Device and PoNS Treatment™
The Portable Neuromodulation Stimulator (PoNS™) is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from multiple sclerosis (MS), and chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”). The device is currently under review for clearance by the FDA. It is also under premarket review by the AUS Therapeutic Goods Administration. PoNS™ is currently not commercially available in the United States, the European Union or Australia.
Investor Relations Contact
:
Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Mike Piccinino, CFA
View comments
相关文章
Mitch Gould and Nutritional Products International Welcome Record-Shattering GDP for Third Quarter
U.S. Gross Domestic Product Surged by 33.1 Percent from July Through SeptemberMitch Gould, the found2024-09-29Big Bang Theory’ Jim Parsons Believes ‘Warm’ Kaley Cuoco Will Be An ‘Incredible’ Mom
"The Big Bang Theory" alumKaley Cuocois receiving the warmest compliments from her former co-starJim2024-09-29Does Elisa Oyj (HEL:ELISA) Have A Place In Your Portfolio?
Want to participate in ashort research study? Help shape the future of investing tools and receive a2024-09-29Have Insiders Been Buying Alfa Laval AB (publ) (STO:ALFA) Shares?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunat2024-09-29- London, June 05, 2020 (GLOBE NEWSWIRE) -- Vaccines represent one of the greatest achievements of sci2024-09-29
Have Insiders Been Selling Delta Air Lines, Inc. (NYSE:DAL) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the othe2024-09-29
最新评论